作者
Samukelisiwe C Shabalala, Phiwayinkosi V Dludla, Lawrence Mabasa, Abidemi P Kappo, Albertus K Basson, Carmen Pheiffer, Rabia Johnson
发表日期
2020/11/1
来源
Biomedicine & pharmacotherapy
卷号
131
页码范围
110785
出版商
Elsevier Masson
简介
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide, as it affects up to 30 % of adults in Western countries. Moreover, NAFLD is also considered an independent risk factor for cardiovascular diseases. Insulin resistance and inflammation have been identified as key factors in the pathophysiology of NAFLD. Although the mechanisms associated with the development of NAFLD remain to be fully elucidated, a complex interaction between adipokines and cytokines appear to play a crucial role in the development of this condition. Adiponectin is the most common adipokine known to be inversely linked with insulin resistance, lipid accumulation, inflammation and NAFLD. Consequently, the focus has been on the use of new therapies that may enhance hepatic expression of adiponectin downstream targets or increase the serum levels of adiponectin in the treatment …
引用总数
20202021202220232024222283830